KNSA Q4 2018 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$44M

Net Income

-$43M

EPS (Diluted)

$-0.88

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$32M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$322M

Total Liabilities

$43M

Stockholders' Equity

$279M

Cash & Equivalents

$307M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$44M	-$33M	-34.9%
Net Income	-$43M	-$33M	-30.2%